SLC22A8 Antibody - #DF7196

Figure 4. Effects of PCE and PCW on renal ABCG2, OAT3, OAT1 and OCT2 protein expression detected by Western blot: immunoreactive bands (a) and densitometries (b,c,d and –e, expressed as mean ± SD; n n ¼ 3).  p < 0.05,  p < 0.01 versus the normal control; #p < 0.05, ##p < 0.01 versus the hyperuricemic control;

p < 0.01 versus the allopurinol control.

Figure 4. | XRF promoted MTX secretion into urine in CIA rats.; B, effects of treatments on OAT3 expression in kidney, investigated by the immunoblotting method, **p < 0.01 compared with CIA models, ##p < 0.01 compared with MTX treated rats

Fig. 4. Effects of CP-25 on renal OAT3 expression and function in vivo. A: the renal excretion of MTX were measured in rats that received a single intravenous injection of MTX (5 mg/kg). B: the tissue extracts were prepared, and the lysate was resolved by SDS-PAGE and probed with antibodies against OAT3. C: OAT3 function was evaluated by detecting DHEA excretion in the rats received a single intravenous injection of DHEA (20 mg/kg). The data are presented as the means ± S.D. (n ¼ 6). ##P < 0.01 compared with normal group; *P < 0.05, **P < 0.01 compared with the model group (MTX).

Fig. 7. Western blot results and analysis. A: The expression of the uric acid transporter protein ABCG2, OAT3, and GLUT9 in the kidney of hyperuricemic rats.